134577-96-1

Downstream Products

• 150598-56-4 3-(3-ethoxy-3-oxopropyl)-4-hydroxy-δ-oxobenzenepentanoic acid ethyl ester 
• 141773-90-2 5-[4-hydroxy-3-(2-methoxycarbonylethyl)-phenyl]-5-oxopentanoic acid methyl ester 
• 197707-94-1 ethyl-4-{3-[2-(ethoxycarbonyl)ethyl]-4-[6-(4-methoxyphenyl)-(5E)-hexenyloxy]phenylcarbonyl}butanoate 
• 197707-96-3 ethyl-5-{3-[2-(ethoxycarbonyl)ethyl]-5-hydroxy-4-[6-(4-methoxyphenyl)-(5E)-hexenyloxy]phenyl}pentanoate 
• 197707-95-2 ethyl-3-{2-[6-(4-methoxyphenyl)-(5E)-hexenyloxy]-5-[4-(dimethylaminocarbonyl)butanoyl]phenyl}propanoate 
• 197707-97-4 ethyl-3-{5-[4-(dimethylaminocarbonyl)-1-hydroxybutyl]-2-[6-(4-methoxyphenyl)-(5E)-hexenyloxy]phenyl}propanoate 
• 197707-93-0 ethyl-3-{5-[4-(dimethylaminocarbonyl)butanoyl]-2-hydroxyphenyl}propanoate 

Relevant academic research and scientific papers

LEUKOTRIENE-B4 ANTAGONIST COMPOUNDS AND THEIR USE AS PHARMACEUTICAL AGENTS

1. Leukotriene-B 4 antagonists of formula I STR1 are described, in which X is a CH 2 group or an oxygen atom,Y is C. sub.1-C 4-alkoxy or--S(O) p--C 1-C 4-alkyl,p is 0, 1 or 2Z is a hydrogen atom or the radical A-B-COOH with A being a hydroxymethylene group or a carbonyl group and B being an alkylene group with 1-6 atoms in the chain or a radical STR2 with the exception that B cannot mean the radical STR3 if X is a CH. sub.2 group, R 1 is the radical OH,--O--(C 1--C 4)-alkyl,--O--(C 3-C 6)-cycloalkyl,--O--(C 7-C. sub.12)-aralkyl or the radical NHR 4 with R 4 being hydrogen, (C. sub.1-C 4)-alkyl, (C 3-C 6)-cycloalkyl, C 6-C 10-aryl or (C 7-C 12)-aralkyl as well as their salts with physiologically compatible bases and their cyclodextrin clathrates, process for their production and their use as pharmaceutical agents.